Testing Temozolomide with Veliparib or Placebo in Specific Patients with Newly Diagnosed Glioblastoma Multiforme

June 26, 2016
A071102
Brain and Neural
William Broderick, MD
Edward Cancer Center - Naperville
Edward Cancer Center - Plainfield

To compare the effects, good or bad of the usual treatment (temozolomide) with or without the addition of the investigational drug veliparib for people whose brain tumors show a change in a small region of DNA.

Sponsor: Alliance for Clinical Trials in Oncology

https://clinicaltrials.gov/ct2/show/NCT02152982

  • Grade IV glioblastoma or gliosarcoma
  • Complete resection, partial resection, or biopsy
  • Deemed to have progressive disease
  • Must have completed standard radiotherapy and concimitant TMZ therapy
5 years
Closed
Interventional
II/III
Kathy Seymour, BSN
630-646-6075
630-646-6110
630-646-6072